When protein hits your digestive tract, it stimulates insulin secretion and promotes GLP-1 output at the same time, a double benefit for blood sugar stability
Variations in the GLP1R gene (such as rs6923761) and the GIPR gene (rs1800437) affect receptor density and signaling efficiency, meaning some individuals experience pronounced early symptoms while others feel minimal disruption
the most significant safety concerns are associated with high-dose, unregulated use in non-clinical settings
Elevated levels of cholesterol carried by apolipoprotein B (apoB) (non-high-density lipoprotein cholesterol [HDL-C] and low-density lipoprotein-C [LDL-C]) is a root cause of atherosclerosis and reducing levels of atherogenic cholesterol lowers atherosclerotic cardiovascular disease (ASCVD) risk [12]
For individuals taking GLP-1 medications (e.g., Ozempic, Wegovy, or Mounjaro), making thoughtful choices about meals and snacks can help support overall dietary goals
Zealand and Boehringer Ingelheim have survodutide in Phase 3 trials and is included in the GLP1 Pipeline Update